
Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target
Adaptive Biotechnologies (ADPT) Analyst Ratings
Bulls say
Adaptive Biotechnologies Corp is positioned for robust financial growth, primarily driven by anticipated increases in average selling prices (ASPs) and clinical mix shifts, which are expected to enhance gross profit. The transition to NovaSeq X is projected to improve sequencing margins, contributing to a favorable gross margin outlook as the company scales its capabilities. Furthermore, with incremental volume growth and ASP improvements anticipated for 2025, the financial outlook for the minimal residual disease (MRD) market is expected to strengthen, further supporting the company's revenue growth potential.
Bears say
The financial outlook for Adaptive Biotechnologies Corp indicates a stagnation in Immune Medicine revenue, with no growth anticipated as the company focuses on generating interest in its TCR-Antigen model and developing its autoimmunity program. A significant challenge arises from the data showing that approximately 25% of patients who receive an ID test do not go on to receive a minimal residual disease (MRD) test within 12 months, which negatively impacts the frequency of testing and potential revenue. Despite being recognized as a leader in the market for immune-driven medicine, the inherent limitations in patient testing rates and the flat revenue forecast contribute to a negative outlook for the company’s stock.
This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.
Adaptive Biotechnologies (ADPT) Analyst Forecast & Price Prediction
Start investing in Adaptive Biotechnologies (ADPT)
Order type
Buy in
Order amount
Est. shares
0 shares